In the current studies, we have used transgenic mice, allowing precise targeting of donor T cell IL-33 signaling or recipient expression of IL-33 in multiple alloHCT models of CD4+ T cell–mediated GVHD, to make what we believe are novel observations into how stromal cell–derived, DAMP-mediated stimulation of donor T cells is critical to pathologic alloimmune responses after alloHCT. Here, IL33 is linked to graft versus host disease.